What is the recommended dosing for Colesevelam (bile acid sequestrant)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Colesevelam Dosing

For adults with primary hyperlipidemia, the recommended dose of colesevelam is 3.75 grams daily, administered either as 6 tablets (625 mg each) once daily or 3 tablets twice daily with meals, or as one 3.75-gram oral suspension packet once daily mixed with 4-8 ounces of liquid and taken with a meal. 1, 2

Standard Adult Dosing Regimens

Tablet Formulation

  • 6 tablets (625 mg each) once daily with a meal and liquid 1, 3, 2
  • Alternative: 3 tablets twice daily with meals and liquid 1, 3, 2

Oral Suspension Formulation

  • One 3.75-gram packet once daily mixed with 4-8 ounces of water, fruit juice, or diet soft drink, taken with a meal 1, 3, 2
  • Alternative: One 1.875-gram packet twice daily (equivalent to 3 tablets per dose) 1, 3

Pediatric Dosing (Ages 10-17 Years)

For boys and postmenarchal girls aged 10-17 years with heterozygous familial hypercholesterolemia, the recommended dose is 3.75 grams daily, administered as monotherapy or in combination with a statin. 1, 2, 4

  • The same dosing regimens apply as for adults (6 tablets once daily or 3 tablets twice daily with meals) 2, 4
  • This dosing has been studied for up to 26 weeks in pediatric patients and demonstrated sustained efficacy and tolerability 4

Expected LDL-C Reduction

Monotherapy

  • Colesevelam 3.75 grams daily as monotherapy reduces LDL-C by approximately 15% 1

Combination Therapy with Statins

  • When added to low- to moderate-intensity statins, colesevelam provides an additional 10-16% reduction in LDL-C 1
  • Combination therapy appears more effective than monotherapy for achieving LDL-C goals 5

Critical Administration Requirements

Timing with Meals

Colesevelam must be taken with meals to ensure optimal interaction with bile acids released during digestion. 3

  • The drug binds bile acids in the intestine, which are released during meal digestion 3
  • Taking with food maximizes bile acid sequestration and lipid-lowering efficacy 3
  • Practical scheduling: Take with breakfast and/or dinner 3

Drug Interaction Management

All other medications must be taken at least 1 hour before or 4 hours after colesevelam to avoid impaired absorption. 1, 3, 2

High-Risk Medications Requiring Strict Separation

The following drugs have narrow therapeutic windows and require careful timing 1, 3, 2:

  • Thyroid hormone replacement therapy
  • Warfarin
  • Phenytoin
  • Oral contraceptives (ethinyl estradiol/norethindrone)
  • Cyclosporine
  • Olmesartan medoxomil
  • Sulfonylureas (glimepiride, glipizide, glyburide)

Practical implementation: Take other medications either first thing in the morning (1+ hours before colesevelam) or at bedtime (4+ hours after colesevelam). 3

Special Populations and Considerations

Type 2 Diabetes

  • Colesevelam 3.75 grams daily is FDA-approved as adjunct therapy to improve glycemic control in adults with type 2 diabetes 1, 2
  • The drug lowers HbA1c by approximately 0.5% when used in diabetic patients 1
  • Long-term use (52 weeks) demonstrated safety without weight gain (mean 0.2 kg reduction) 6

Bile Acid Diarrhea (Off-Label)

  • For bile acid diarrhea, colesevelam is typically dosed as 2 tablets (625 mg) three times daily with meals 1
  • Colesevelam is generally reserved as second-line therapy after cholestyramine failure or intolerance 1
  • Success rate as second-line therapy ranges from 42-100% in observational studies 1

Contraindications

Do not use colesevelam in patients with: 2

  • Serum triglyceride levels >500 mg/dL
  • History of hypertriglyceridemia-induced pancreatitis
  • History of bowel obstruction
  • Complete biliary obstruction

Safety and Tolerability Profile

Common Adverse Effects

The most common adverse effects are gastrointestinal: constipation, dyspepsia, and nausea, occurring at rates similar to placebo (approximately 40%). 1

  • In long-term studies (52 weeks), 70.9% of patients experienced adverse events, with 88.1% being mild or moderate 6
  • Only 6.9% discontinued due to adverse events 6
  • Colesevelam has significantly better tolerability than traditional bile acid sequestrants like cholestyramine 1, 7

Compliance Advantages

  • Compliance rates with colesevelam reach 93%, substantially higher than traditional bile acid sequestrants 7
  • The tablet formulation eliminates the palatability issues associated with cholestyramine powder 1
  • Colesevelam is 4-6 times more potent than traditional bile acid sequestrants, allowing for lower pill burden 7

Clinical Pearls and Pitfalls

Vitamin Supplementation

Patients requiring oral vitamin supplementation (especially fat-soluble vitamins A, D, E, K) should take vitamins at least 4 hours before colesevelam. 1, 2

  • Patients on warfarin are at particular risk for vitamin K deficiency 2
  • Patients with malabsorption syndromes require monitoring for fat-soluble vitamin deficiencies 2

Triglyceride Monitoring

Monitor triglyceride levels before starting and periodically during therapy, as colesevelam may increase triglycerides. 2

  • Instruct patients to discontinue colesevelam and seek immediate medical attention if symptoms of acute pancreatitis develop 2

Phenylketonuria Warning

Colesevelam oral suspension contains 33.6 mg phenylalanine per 3.75-gram packet and should be avoided in patients with PKU. 2

Gastrointestinal Motility Disorders

Colesevelam is not recommended in patients with gastroparesis, other GI motility disorders, or those who have had major GI surgery due to risk of bowel obstruction. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Colesevelam Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010

Research

Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2010

Research

Colesevelam hydrochloride.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.